Cargando…
Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry
Cancer of unknown primary (CUP) accounts for 5% of all malignancies. Patients with CUP may live averagely for 8 months after diagnosis, and thus, rapid and reasonable diagnosis is necessary. Among patients with CUP, anaplastic lymphoma kinase (ALK)-overexpressing CUPs, whose primary sites were confi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832189/ https://www.ncbi.nlm.nih.gov/pubmed/35221965 http://dx.doi.org/10.1159/000521157 |
_version_ | 1784648673162952704 |
---|---|
author | Kato, Yoriko Shimazu, Kazuhiro Fukuda, Koji Yoshida, Taichi Taguchi, Daiki Shinozaki, Hanae Nanjyo, Hiroshi Shibata, Hiroyuki |
author_facet | Kato, Yoriko Shimazu, Kazuhiro Fukuda, Koji Yoshida, Taichi Taguchi, Daiki Shinozaki, Hanae Nanjyo, Hiroshi Shibata, Hiroyuki |
author_sort | Kato, Yoriko |
collection | PubMed |
description | Cancer of unknown primary (CUP) accounts for 5% of all malignancies. Patients with CUP may live averagely for 8 months after diagnosis, and thus, rapid and reasonable diagnosis is necessary. Among patients with CUP, anaplastic lymphoma kinase (ALK)-overexpressing CUPs, whose primary sites were confirmed to be the lungs (Lung-CUP) by using antibodies against cytokeratin 7, thyroid transcription factor-1, and Napsin A, along with clinical characteristics progressed rapidly and were very sensitive to the ALK inhibitor alectinib. The incidence of ALK alteration in Lung-CUP is 19%. Consequently, it is advised that Lung-CUP be examined by immunohistochemistry (IHC) with an anti-ALK antibody. Alternative examinations, such as a cancer genome test, require as much as 2 months to complete, whereas IHC can be completed within days. In this report, a rapid assessment by IHC led to alectinib treatment, which resulted in good outcomes in 2 cases of Lung-CUP. Alectinib was effective for ALK-altered Lung-CUPs. |
format | Online Article Text |
id | pubmed-8832189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-88321892022-02-25 Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry Kato, Yoriko Shimazu, Kazuhiro Fukuda, Koji Yoshida, Taichi Taguchi, Daiki Shinozaki, Hanae Nanjyo, Hiroshi Shibata, Hiroyuki Case Rep Oncol Case Report Cancer of unknown primary (CUP) accounts for 5% of all malignancies. Patients with CUP may live averagely for 8 months after diagnosis, and thus, rapid and reasonable diagnosis is necessary. Among patients with CUP, anaplastic lymphoma kinase (ALK)-overexpressing CUPs, whose primary sites were confirmed to be the lungs (Lung-CUP) by using antibodies against cytokeratin 7, thyroid transcription factor-1, and Napsin A, along with clinical characteristics progressed rapidly and were very sensitive to the ALK inhibitor alectinib. The incidence of ALK alteration in Lung-CUP is 19%. Consequently, it is advised that Lung-CUP be examined by immunohistochemistry (IHC) with an anti-ALK antibody. Alternative examinations, such as a cancer genome test, require as much as 2 months to complete, whereas IHC can be completed within days. In this report, a rapid assessment by IHC led to alectinib treatment, which resulted in good outcomes in 2 cases of Lung-CUP. Alectinib was effective for ALK-altered Lung-CUPs. S. Karger AG 2022-01-17 /pmc/articles/PMC8832189/ /pubmed/35221965 http://dx.doi.org/10.1159/000521157 Text en Copyright © 2022 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Kato, Yoriko Shimazu, Kazuhiro Fukuda, Koji Yoshida, Taichi Taguchi, Daiki Shinozaki, Hanae Nanjyo, Hiroshi Shibata, Hiroyuki Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry |
title | Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry |
title_full | Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry |
title_fullStr | Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry |
title_full_unstemmed | Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry |
title_short | Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry |
title_sort | two cases of alk-altered cancers of unknown primary diagnosed by immunohistochemistry |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832189/ https://www.ncbi.nlm.nih.gov/pubmed/35221965 http://dx.doi.org/10.1159/000521157 |
work_keys_str_mv | AT katoyoriko twocasesofalkalteredcancersofunknownprimarydiagnosedbyimmunohistochemistry AT shimazukazuhiro twocasesofalkalteredcancersofunknownprimarydiagnosedbyimmunohistochemistry AT fukudakoji twocasesofalkalteredcancersofunknownprimarydiagnosedbyimmunohistochemistry AT yoshidataichi twocasesofalkalteredcancersofunknownprimarydiagnosedbyimmunohistochemistry AT taguchidaiki twocasesofalkalteredcancersofunknownprimarydiagnosedbyimmunohistochemistry AT shinozakihanae twocasesofalkalteredcancersofunknownprimarydiagnosedbyimmunohistochemistry AT nanjyohiroshi twocasesofalkalteredcancersofunknownprimarydiagnosedbyimmunohistochemistry AT shibatahiroyuki twocasesofalkalteredcancersofunknownprimarydiagnosedbyimmunohistochemistry |